UNSPSC 51343307: Rociclovir

This classification denotes a purine antagonist and antiviral agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6DF29U51Y7. European Medicines Agency schedules Rociclovir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10351MIG. Rociclovir generally arises in the molecular formula C15H25N5O3. The term ROCICLOVIR is an International Non-Proprietary Name or INN. ROCICLOVIR is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

Most nations schedule rociclovir under HS 29335995 and SITC 51576. As of Q4 2014, ROCICLOVIR remains the US FDA Preferred Term for this commodity. Rociclovir bears US NLM identifiers UMLS ID C0643822 and NCI Concept Code C73204. SMILES: O(C(COC(C)C)COC(C)C)CN1C2NC(NCC2NC1)N.

UNSPSC 51343307 Rociclovir, a Commodity code, reflects state and local procurement of antiviral pharmaceuticals, though recent opportunities tagged under this code diverge significantly from the rociclovir-specific nomenclature. The source shows only two recent state and local opportunities, neither directly matching the code's nominal product scope. The Illinois Department of Public Health awarded a completed piggyback pharmaceutical warehouse contract through the MMCAP Infuse consortium to Chartwell Rx LLC in August 2026 for Doxycycline Hyclate and Ciprofloxacin Hydrochloride, separate from rociclovir. Seminole County, Florida solicited Naloxone and Safe Drug Deactivation Systems through an IFB posted in June 2026, again outside the rociclovir category. The issuing bodies observed are a state health department and a county government, both sourcing pharmaceuticals through competitive bidding or cooperative purchasing vehicles for public health and emergency-preparedness uses. The mismatch between the code's stated product and the actual opportunities suggests either commodity-code assignment drift in the source data or limited recent demand for rociclovir specifically under this classification.

Geographic activity centers on Florida and Illinois based on the two recent opportunities. The Illinois contract, totaling $2,999,999.11 over 12 months plus two optional renewal years, demonstrates significant pharmaceutical procurement volume through state-level cooperative purchasing. Seminole County's procurement, posted July 2026 with response due July 26, 2026, calls for annual delivery of 1,900 units of Naloxone and 800 deactivation systems on a two-year initial term with one-year renewal option, though the due date listed (July 26, 2023) appears inconsistent with the posting date and likely reflects a data quality issue. The Illinois opportunity noted no set-aside or veteran-preference utilization. No other states show recent rociclovir-specific solicitations in the source block. Activity under this code appears minimal and largely misaligned with the rociclovir product designation.